United States Patent 8,404,276: Scope, Claims, and US Patent Landscape for Inhaled/Respiratory Levodopa in Parkinson’s

United States Patent 8,404,276 covers methods of treating Parkinson’s disease by administering inhalable particles to the respiratory tract. The claims converge on a consistent formulation architecture: high-dose levodopa particles (about 90 wt% or more) combined with sodium chloride and a phospholipid (with DPPC specifically claimed), delivered to the pulmonary system using a particle profile defined by tap density and aerodynamic diameter.

This is a method-of-treatment and method-of-delivery patent, with scope concentrated in three claim “clusters”: 1) Composition plus pulmonary delivery (levodopa + sodium chloride + phospholipid, delivered to the lung).
2) Particle engineering parameters (tap density and aerodynamic diameter).
3) Specific compositional ratios and DPPC.

What claims does US 8,404,276 actually cover?

H2: Core claim set (claims 1, 8, 13)

These claims define the baseline scope: high levodopa loading + sodium chloride + phospholipid + pulmonary delivery.

Claim 1

Treat Parkinson’s disease by:
- Administering to the respiratory tract particles including about 90 wt% levodopa or more
- A salt that is sodium chloride
- A phospholipid
- Delivered to the pulmonary system

Claim 8

Similar baseline, with slight wording and an expanded phospholipid definition:
- Particles include about 90 wt% levodopa or more
- Sodium chloride
- phospholipid or combination of phospholipids
- Delivered to the pulmonary system

Claim 13

A shorter variant of the baseline:
- Particles comprising levodopa + sodium chloride + (phospholipid not expressly recited in claim 13 as provided by you, but your input frames it as included in the particle system)
- Delivered to the pulmonary system
- (Your provided text for claim 13 reads “particles comprising levodopa, sodium chloride and dipalmitoyl phosphatidylcholine” in claim 14, but claim 13 in your text is truncated to omit the phospholipid term. The literal text you supplied for claim 13 states only levodopa and sodium chloride plus pulmonary delivery; that would narrow to a formulation still “particles” but without requiring a phospholipid in claim 13 as written.)

Practical meaning: If a competitor makes inhalable levodopa particles in the lung with sodium chloride and a phospholipid, they land inside the claim family. If they omit sodium chloride or phospholipid, they likely avoid this cluster.

H2: Sodium chloride and DPPC-limited embodiments (claims 9, 10, 12, 14)

These claims tighten the scope using compositional cutoffs.

Claim 9

Particles comprise 3 wt% or less sodium chloride

Claim 10

Phospholipid is dipalmitoyl phosphatidylcholine (DPPC)

Claim 12

Particles comprise 3 wt% or less sodium chloride
(Dependent from claim 11/3 per your list)

Claim 14

Fixed ratio formulation:
- Administer to respiratory tract particles with:
- levodopa
- sodium chloride
- DPPC
- Ratio levodopa:DPPC:sodium chloride = 90:8:2

Practical meaning: Claim coverage expands from “any phospholipid” (claims 1, 8) into DPPC-specific scope (claim 10 and claim 14). The sodium chloride limitation becomes a key design variable: keeping sodium chloride at or below 3 wt% brings in claims 9 and 12; the strict ratio claim 14 is a precise target.

H2: Particle engineering constraints (claims 2–7)

This is the most technically constraining portion of the claim set: it defines particle properties that control deposition in the respiratory tract.

Claim 2 (dependent architecture with major parameter definitions)

Parkinson’s treatment via pulmonary delivery of particles that consist essentially of:
- about 90 wt% or more levodopa
- an optional non-reducing sugar
- a phospholipid
- a salt = sodium chloride
Plus required particle properties:
- tap density < 0.4 g/cm³
- volume median geometric diameter > 5 micrometers
- aerodynamic diameter from 1 micrometer to 5 micrometers

Claims 3–7 narrow aerodynamic diameter and tap density:

Claim 3: Aerodynamic diameter from 1 to 3 µm
Claim 4: Aerodynamic diameter from 3 to 5 µm
Claim 5: tap density < 0.3 g/cm³
Claim 6: tap density < 0.2 g/cm³
Claim 7: tap density < 0.1 g/cm³

Practical meaning: A competitor can try to avoid the engineered-particle limitations by:

using different particle-size distributions (aerodynamic diameter outside 1–5 µm, or volume median geometric diameter not > 5 µm), or
exceeding the tap density thresholds (e.g., >0.4 g/cm³). But note: these constraints appear in claim 2 and are then narrowed in dependent claims. Independent baseline claims (1, 8, 13) do not, based on your provided text, require the tap density and aerodynamic profile.

H2: Delivery method claim with “simultaneous dispersion and inhalation” (claim 11)

Claim 11 defines a procedural delivery mechanism and composition ratio.

Claim 11

Method of delivering L-Dopa to pulmonary system:
- Provide a mass of particles comprising by weight:
- about 90% or more L-Dopa
- sodium chloride
- about 10% or less DPPC
- Administer via simultaneous dispersion and inhalation
- From a receptacle to a human subject’s respiratory tract

Claim 11 is a delivery-process constraint: A system that delivers via a different mechanism (not “simultaneous dispersion and inhalation,” as written) may fall outside claim 11 even if it uses the same formulation.

How broad is the scope across formulations?

H2: Composition breadth vs. parameter specificity

Based on the claim text provided, the patent splits into:

Broad formulation scope in the independent-ish baseline claims:
- “Particles including about 90 wt% levodopa or more”
- “salt is sodium chloride”
- “phospholipid”
- delivered to pulmonary system
  (Claims 1 and 8)
Narrower formulation scope with strict engineering and/or constraints:
- “consist essentially of” with added “optional non-reducing sugar” (claim 2)
- tap density limits (claims 2, 5–7)
- aerodynamic diameter window (claim 2, plus dependent splits)
- explicit DPPC identity (claim 10)
- explicit sodium chloride wt% cap (claims 9, 12)
- explicit ratio (claim 14)
- delivery mechanism constraint (claim 11)

H2: “Consist essentially of” impact (claim 2)

Claim 2 uses “particles consist essentially of”:

about 90 wt% or more levodopa
optional non-reducing sugar
phospholipid
sodium chloride

This language typically tolerates minor components that do not materially affect basic and novel characteristics. Operationally, it tightens freedom-to-operate because impurities, excipients, or carrier-like additives could be argued to be outside the “consist essentially of” boundary if they materially change performance or deposition behavior.

Claim-by-claim infringement exposure map (design levers)

Design variable	Claim(s) directly tied	If you move this outside the stated range, you reduce risk
Levodopa loading	Claims 1, 2, 8, 11, 13	Reduce below “about 90 wt% or more”
Salt identity	Claims 1, 2, 8, 11	Replace sodium chloride with a different salt
Phospholipid presence/type	Claims 1, 2, 8, 10, 11, 14	Remove phospholipid, or use a non-phospholipid system; for DPPC-only scope, avoid DPPC
Sodium chloride wt% cap	Claims 9, 12, (also composition context in 14)	Keep above 3 wt% to avoid the ≤3% dependent claims, or lock into different salt composition
DPPC	Claims 10, 11 (≤10% DPPC), 14	Use another phospholipid if trying to avoid DPPC-specific claims
Tap density	Claims 2, 5–7	Raise tap density to ≥0.4 g/cm³ (or above specific thresholds)
Volume median geometric diameter	Claim 2	Make it ≤5 µm
Aerodynamic diameter	Claims 2–4	Move outside 1–5 µm (or 1–3 and 3–5 splits)
Delivery mechanism	Claim 11	Use non “simultaneous dispersion and inhalation” process

What the patent landscape implies for US Freedom-to-Operate

H2: Where competitors are most likely caught

The risk concentrates where programs pursue the same combination of:

inhalable/respiratory deposition particles, not oral delivery
levodopa as the dominant component
sodium chloride + phospholipid, especially DPPC
engineered particle properties tuned to aerodynamic diameter

Many inhalation drug platforms use engineered powders, carriers, spray drying, or different excipient systems; this patent narrows to a specific “formulation plus deposition targeting” signature. If an R&D program targets lung delivery of levodopa, it typically overlaps with the same fundamentals, even if the particle-making method differs.

H2: Likely design-around strategies (based strictly on claim scope)

The most direct ways to move out of this claim set, based on the text you provided:

Change the salt: sodium chloride is required in claims 1, 2, 8, 11, 13. Switching to a different salt is the cleanest escape from multiple independent/broad claims.
Remove or change the phospholipid requirement: claim 1 and claim 8 require phospholipids; claim 10/14 require DPPC.
Break the engineered particle spec: for claim 2–7, shift tap density or aerodynamic diameter out of the stated ranges.
Change delivery method: claim 11 requires “simultaneous dispersion and inhalation.” A delivery system that does not perform that function could avoid claim 11.

Key takeaways

US 8,404,276 covers lung delivery of high-loading levodopa particles using sodium chloride plus a phospholipid as formulation elements.
The patent has two claim layers: (1) broad “composition + pulmonary delivery” claims and (2) narrower particle-parameter claims (tap density, volume median geometric diameter, aerodynamic diameter).
DPPC and tight sodium chloride limits are expressly claimed (DPPC identity in claim 10; ≤3 wt% sodium chloride in claims 9 and 12; fixed ratio 90:8:2 in claim 14).
The most leverage for claim avoidance is to change sodium chloride identity, remove/replace phospholipids, or shift particle deposition parameters; delivery mechanism is a second lever via “simultaneous dispersion and inhalation” in claim 11.

FAQs

1) What is the central technical concept of US 8,404,276?

Pulmonary administration of particles where levodopa is ~90 wt% or more, formulated with sodium chloride and a phospholipid, with optional additional constraints on aerodynamic diameter and tap density.

2) Does the patent require DPPC in all claims?

No. DPPC is explicitly required in claim 10 and appears in the fixed ratio claim 14. Other claims require “a phospholipid” more generally, and claim 11 limits DPPC to about 10% or less.

3) Are particle size and tap density mandatory for infringement?

Not for the broad baseline claims as provided (claims 1 and 8 do not state tap density or aerodynamic diameter). They are mandatory for the engineered-parameter branch beginning at claim 2.

4) What is the strictest aerodynamic diameter coverage?

Claim 2 defines 1 µm to 5 µm, and dependent claims split it into:

1 to 3 µm (claim 3) and
3 to 5 µm (claim 4).

5) Does US 8,404,276 cover device operation or only powder formulation?

It covers both:

powder/formulation scope via composition and particle parameters, and
a delivery-process requirement in claim 11: “simultaneous dispersion and inhalation.”

References

[1] United States Patent 8,404,276 (claim set provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003218307	⤷ Start Trial
Canada	2478980	⤷ Start Trial
Cyprus	1118517	⤷ Start Trial
Denmark	1531798	⤷ Start Trial
Denmark	2630954	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,404,276

Summary for Patent: 8,404,276